Company description
ValveStrong will commercialize hybrid heart valve prostheses with self-regenerative capacity, lifelong durability, and enhanced biocompatibility. Since ValveStrong’s technology can be incorporated into both surgical and transcatheter valves, it has a competitive cost structure with the potential to capture a significant portion of the $1.5 billion current annual worldwide heart valve replacement market.